Stockscreener 앱 받기
23.98
1.84%
-0.45
시간 외 거래:
23.98
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Rare Disease Breakthrough: Palvella CEO Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com
Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World
Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World
Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Insider Monkey
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - MarketScreener
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading - Defense World
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada
Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com
Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com
Palvella Therapeutics initiated with a Buy at Stifel - TipRanks
Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire
Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq
Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan
Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance
Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
PavellaUndiscovered Biotechnology Stock - TradingView
PalvellaUndiscovered Biotechnology Stock - Barchart
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com
Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK
Palvella Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Palvella Therapeutics Enhances Investor Relations with New Presentation - TipRanks
10.70%
자본화:
|
볼륨(24시간):